A small study looking at anti-PD(L)1 immunotherapy compared the outcomes of MASLD-HCC patients (n = 13) to those with other aetiologies (n = 117) and demonstrated reduced OS in the MASLD-HCC group [64]. This evidence concerns the gene CD274 and hepatocellular carcinoma.